Victory Capital Management Inc. Sells 13,032 Shares of Stryker Co. (NYSE:SYK)

Victory Capital Management Inc. trimmed its stake in shares of Stryker Co. (NYSE:SYK - Free Report) by 8.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 150,790 shares of the medical technology company's stock after selling 13,032 shares during the quarter. Victory Capital Management Inc.'s holdings in Stryker were worth $54,292,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in SYK. State Street Corp increased its position in Stryker by 2.2% in the 3rd quarter. State Street Corp now owns 14,582,959 shares of the medical technology company's stock valued at $5,279,788,000 after acquiring an additional 316,404 shares during the period. FMR LLC increased its position in Stryker by 3.0% in the 3rd quarter. FMR LLC now owns 7,306,994 shares of the medical technology company's stock valued at $2,639,725,000 after acquiring an additional 215,782 shares during the period. Geode Capital Management LLC increased its position in Stryker by 2.5% in the 3rd quarter. Geode Capital Management LLC now owns 6,905,126 shares of the medical technology company's stock valued at $2,484,893,000 after acquiring an additional 165,490 shares during the period. Parnassus Investments LLC acquired a new stake in Stryker in the 3rd quarter valued at approximately $762,798,000. Finally, Charles Schwab Investment Management Inc. increased its position in Stryker by 2.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,985,045 shares of the medical technology company's stock valued at $714,715,000 after acquiring an additional 48,819 shares during the period. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Stryker Stock Down 0.8 %

Shares of NYSE:SYK traded down $3.03 during midday trading on Friday, hitting $379.28. 1,961,830 shares of the stock were exchanged, compared to its average volume of 1,209,637. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. Stryker Co. has a 52-week low of $314.93 and a 52-week high of $406.19. The business's fifty day simple moving average is $382.45 and its two-hundred day simple moving average is $372.99. The company has a market capitalization of $144.73 billion, a PE ratio of 48.88, a P/E/G ratio of 2.93 and a beta of 0.95.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter last year, the business earned $3.46 earnings per share. As a group, research analysts predict that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a dividend of $0.84 per share. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.89%. Stryker's dividend payout ratio (DPR) is currently 43.30%.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now directly owns 14,895 shares in the company, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company's stock.

Analyst Upgrades and Downgrades

SYK has been the topic of several research analyst reports. Wells Fargo & Company lifted their price target on Stryker from $427.00 to $435.00 and gave the company an "overweight" rating in a research report on Wednesday, January 29th. Barclays lifted their price target on Stryker from $418.00 to $443.00 and gave the company an "overweight" rating in a research report on Monday, February 10th. StockNews.com cut Stryker from a "buy" rating to a "hold" rating in a research report on Thursday. Argus set a $450.00 price target on Stryker in a research report on Monday, February 3rd. Finally, Royal Bank of Canada lifted their price target on Stryker from $425.00 to $435.00 and gave the company an "outperform" rating in a research report on Wednesday, January 29th. Five investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Stryker presently has an average rating of "Moderate Buy" and a consensus price target of $422.15.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.